1. Sampson HA, Muñoz-Furlong A, Campbell RL, et al.: Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117(2):391–7. 10.1016/j.jaci.2005.12.1303 [PubMed] [CrossRef] [Google Scholar]
2. Johansson SG, Bieber T, Dahl R, et al.: Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832–6. 10.1016/j.jaci.2003.12.591 [PubMed] [CrossRef] [Google Scholar]
3. Muraro A, Roberts G, Worm M, et al.: Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy. 2014;69(8):1026–45. 10.1111/all.12437 [PubMed] [CrossRef] [Google Scholar]
4. Lieberman P, Camargo CA, Bohlke K, et al.: Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Ann Allergy Asthma Immunol. 2006;97(5):596–602. 10.1016/S1081-1206(10)61086-1 [PubMed] [CrossRef] [Google Scholar]
5. Wood RA, Camargo CA, Lieberman P, et al.: Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133(2):461–7. 10.1016/j.jaci.2013.08.016 [PubMed] [CrossRef] [Google Scholar]
6. Lieberman P, Nicklas RA, Oppenheimer J, et al.: The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol. 2010;126(3):477–80.e1–42. 10.1016/j.jaci.2010.06.022 [PubMed] [CrossRef] [Google Scholar]
7. Derby CJ, Gowland MH, Hourihane JO: Sesame allergy in Britain: a questionnaire survey of members of the Anaphylaxis Campaign. Pediatr Allergy Immunol. 2005;16(2):171–5. 10.1111/j.1399-3038.2005.00232.x [PubMed] [CrossRef] [Google Scholar]
8. Gangur V, Kelly C, Navuluri L: Sesame allergy: a growing food allergy of global proportions? Ann Allergy Asthma Immunol. 2005;95(1):4–11; quiz 11-3, 44. 10.1016/S1081-1206(10)61181-7 [PubMed] [CrossRef] [Google Scholar]
9. Stevenson DD: Aspirin and NSAID sensitivity. Immunol Allergy Clin North Am. 2004;24(3):491–505, vii. 10.1016/j.iac.2004.03.001 [PubMed] [CrossRef] [Google Scholar]
10. Patel DD, Goldberg RM: Cetuximab-associated infusion reactions: pathology and management. Oncology (Williston Park). 2006;20(11):1373–82; discussion 1382, 1392–4, 1397. [PubMed] [Google Scholar]
11. Cox L, Platts-Mills TA, Finegold I, et al.: American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol. 2007;120(6):1373–7. 10.1016/j.jaci.2007.09.032 [PubMed] [CrossRef] [Google Scholar]
12. Golden DB: Insect sting allergy and venom immunotherapy: a model and a mystery. J Allergy Clin Immunol. 2005;115(3):439–47; quiz 448. 10.1016/j.jaci.2005.01.005 [PubMed] [CrossRef] [Google Scholar]
13. Golden DB, Marsh DG, Kagey-Sobotka A, et al.: Epidemiology of insect venom sensitivity. JAMA. 1989;262(2):240–4. 10.1001/jama.1989.03430020082033 [PubMed] [CrossRef] [Google Scholar]
14. Dohi M, Suko M, Sugiyama H, et al.: Food-dependent, exercise-induced anaphylaxis: a study on 11 Japanese cases. J Allergy Clin Immunol. 1991;87(1 Pt 1):34–40. 10.1016/0091-6749(91)90210-F [PubMed] [CrossRef] [Google Scholar]
15. Harada S, Horikawa T, Ashida M, et al.: Aspirin enhances the induction of type I allergic symptoms when combined with food and exercise in patients with food-dependent exercise-induced anaphylaxis. Br J Dermatol. 2001;145(2):336–9. 10.1046/j.1365-2133.2001.04329.x [PubMed] [CrossRef] [Google Scholar]
16. Kidd JM, Cohen SH, Sosman AJ, et al.: Food-dependent exercise-induced anaphylaxis. J Allergy Clin Immunol. 1983;71(4):407–11. 10.1016/0091-6749(83)90070-2 [PubMed] [CrossRef] [Google Scholar]
17. Lockey RF, Benedict LM, Turkeltaub PC, et al.: Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol. 1987;79(4):660–77. 10.1016/S0091-6749(87)80164-1 [PubMed] [CrossRef] [Google Scholar]
18. Reid MJ, Lockey RF, Turkeltaub PC, et al.: Survey of fatalities from skin testing and immunotherapy 1985–1989. J Allergy Clin Immunol. 1993;92(1 Pt 1):6–15. 10.1016/0091-6749(93)90030-J [PubMed] [CrossRef] [Google Scholar]
19. Lockey RF, Nicoara-Kasti GL, Theodoropoulos DS, et al.: Systemic reactions and fatalities associated with allergen immunotherapy. Ann Allergy Asthma Immunol. 2001;87(1 Suppl 1):47–55. 10.1016/S1081-1206(10)62195-3 [PubMed] [CrossRef] [Google Scholar]
20. Bernstein DI, Wanner M, Borish L, et al.: Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990–2001. J Allergy Clin Immunol. 2004;113(6):1129–36. 10.1016/j.jaci.2004.02.006 [PubMed] [CrossRef] [Google Scholar]
21. Schwartz LB, Yunginger JW, Miller J, et al.: Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. J Clin Invest. 1989;83(5):1551–5. 10.1172/JCI114051 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
22. Schwartz LB, Bradford TR, Rouse C, et al.: Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis. J Clin Immunol. 1994;14(3):190–204. 10.1007/BF01533368 [PubMed] [CrossRef] [Google Scholar]
23. Schwartz LB: Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am. 2006;26(3):451–63. 10.1016/j.iac.2006.05.010 [PubMed] [CrossRef] [Google Scholar]
24. Schwartz LB, Metcalfe DD, Miller JS, et al.: Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med. 1987;316(26):1622–6. 10.1056/NEJM198706253162603 [PubMed] [CrossRef] [Google Scholar]
25. Valent P, Akin C, Arock M, et al.: Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157(3):215–25. 10.1159/000328760 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
26. Simons FE, Gu X, Simons KJ: Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol. 2001;108(5):871–3. 10.1067/mai.2001.119409 [PubMed] [CrossRef] [Google Scholar]
27. Toogood JH: Risk of anaphylaxis in patients receiving beta-blocker drugs. J Allergy Clin Immunol. 1988;81(1):1–5. 10.1016/0091-6749(88)90212-6 [PubMed] [CrossRef] [Google Scholar]
28. Vander Zanden JA, Valuck RJ, Bunch CL, et al.: Systemic adverse effects of ophthalmic beta-blockers. Ann Pharmacother. 2001;35(12):1633–7. 10.1345/aph.18464 [PubMed] [CrossRef] [Google Scholar]
29. Lang DM, Alpern MB, Visintainer PF, et al.: Increased risk for anaphylactoid reaction from contrast media in patients on beta-adrenergic blockers or with asthma. Ann Intern Med. 1991;115(4):270–6. 10.7326/0003-4819-115-4-270 [PubMed] [CrossRef] [Google Scholar]
30. Pollack CV, Jr: Utility of glucagon in the emergency department. J Emerg Med. 1993;11(2):195–205. 10.1016/0736-4679(93)90519-D [PubMed] [CrossRef] [Google Scholar]
31. Sherman MS, Lazar EJ, Eichacker P: A bronchodilator action of glucagon. J Allergy Clin Immunol. 1988;81(5 Pt 1):908–11. [PubMed] [Google Scholar]
32. Fisher MM: Clinical observations on the pathophysiology and treatment of anaphylactic cardiovascular collapse. Anaesth Intensive Care. 1986;14(1):17–21. [PubMed] [Google Scholar]
33. Fisher M: Blood volume replacement in acute anaphylactic cardiovascular collapse related to anaesthesia. Br J Anaesth. 1977;49(10):1023–6. 10.1093/bja/49.10.1023 [PubMed] [CrossRef] [Google Scholar]
34. Pumphrey RS: Fatal posture in anaphylactic shock. J Allergy Clin Immunol. 2003;112(2):451–2. 10.1067/mai.2003.1614 [PubMed] [CrossRef] [Google Scholar]
35. Sheikh A, Ten Broek V, Brown SG, et al.: H1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review. Allergy. 2007;62(8):830–7. 10.1111/j.1398-9995.2007.01435.x [PubMed] [CrossRef] [Google Scholar]
36. Choo KJL, Simons E, Sheikh A: Glucocorticoids for the treatment of anaphylaxis: Cochrane systematic review. Allergy. 2010;65(10):1205–11. 10.1111/j.1398-9995.2010.02424.x [PubMed] [CrossRef] [Google Scholar]
37. Lieberman P: Biphasic anaphylactic reactions. Ann Allergy Asthma Immunol. 2005;95(3):217–26; quiz 26, 58. 10.1016/S1081-1206(10)61217-3 [PubMed] [CrossRef] [Google Scholar]
38. Alqurashi W, Stiell I, Chan K, et al.: Epidemiology and clinical predictors of biphasic reactions in children with anaphylaxis. Ann Allergy Asthma Immunol. 2015;115(3):217–223.e2. 10.1016/j.anai.2015.05.013 [PubMed] [CrossRef] [Google Scholar]
39. Grunau BE, Li J, Yi TW, et al.: Incidence of clinically important biphasic reactions in emergency department patients with allergic reactions or anaphylaxis. Ann Emerg Med. 2014;63(6):736–44.e2. 10.1016/j.annemergmed.2013.10.017 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation
40. Tole JW, Lieberman P: Biphasic anaphylaxis: review of incidence, clinical predictors, and observation recommendations. Immunol Allergy Clin North Am. 2007;27(2):309–26, viii. 10.1016/j.iac.2007.03.011 [PubMed] [CrossRef] [Google Scholar]
41. Kemp SF: The post-anaphylaxis dilemma: how long is long enough to observe a patient after resolution of symptoms? Curr Allergy Asthma Rep. 2008;8(1):45–8. 10.1007/s11882-008-0009-7 [PubMed] [CrossRef] [Google Scholar]
42. Soar J, Perkins GD, Abbas G, et al.: European Resuscitation Council Guidelines for Resuscitation 2010 Section 8. Cardiac arrest in special circumstances: Electrolyte abnormalities, poisoning, drowning, accidental hypothermia, hyperthermia, asthma, anaphylaxis, cardiac surgery, trauma, pregnancy, electrocution. Resuscitation. 2010;81(10):1400–33. 10.1016/j.resuscitation.2010.08.015 [PubMed] [CrossRef] [Google Scholar]
43. Scranton SE, Gonzalez EG, Waibel KH: Incidence and characteristics of biphasic reactions after allergen immunotherapy. J Allergy Clin Immunol. 2009;123(2):493–8. 10.1016/j.jaci.2008.10.026 [PubMed] [CrossRef] [Google Scholar]
44. Wang J, Sampson HA: Oral and sublingual immunotherapy for food allergy. Asian Pac J Allergy Immunol. 2013;31(3):198–209. [PubMed] [Google Scholar] F1000 Recommendation
45. Burks AW, Wood RA, Jones SM, et al.: Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial. J Allergy Clin Immunol. 2015;135(5):1240–8.e1–3. 10.1016/j.jaci.2014.12.1917 [PMC free article] [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation
46. Sampson HA: Peanut oral immunotherapy: is it ready for clinical practice? J Allergy Clin Immunol Pract. 2013;1(1):15–21. 10.1016/j.jaip.2012.10.009 [PubMed] [CrossRef] [Google Scholar]
48. Wood RA, Sampson HA: Oral immunotherapy for the treatment of peanut allergy: is it ready for prime time? J Allergy Clin Immunol Pract. 2014;2(1):97–8. 10.1016/j.jaip.2013.11.010 [PubMed] [CrossRef] [Google Scholar]
49. Fleischer DM, Burks AW, Vickery BP, et al.: Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J Allergy Clin Immunol. 2013;131(1):119–27.e1–7. 10.1016/j.jaci.2012.11.011 [PMC free article] [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation
51. Goldberg MR, Nachshon L, Appel MY, et al.: Efficacy of baked milk oral immunotherapy in baked milk-reactive allergic patients. J Allergy Clin Immunol. 2015;136(6): pii: S0091-6749(15)00794-0. 10.1016/j.jaci.2015.05.040 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation
53. Raja AS, Lindsell CJ, Bernstein JA, et al.: The use of penicillin skin testing to assess the prevalence of penicillin allergy in an emergency department setting. Ann Emerg Med. 2009;54(1):72–7. 10.1016/j.annemergmed.2008.12.034 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
54. Brockow K, Garvey LH, Aberer W, et al.: Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2013;68(6):702–12. 10.1111/all.12142 [PubMed] [CrossRef] [Google Scholar]
55. Romano A, Caubet JC: Antibiotic allergies in children and adults: from clinical symptoms to skin testing diagnosis. J Allergy Clin Immunol Pract. 2014;2(1):3–12. 10.1016/j.jaip.2013.11.006 [PubMed] [CrossRef] [Google Scholar]
56. Castells M: Rapid desensitization for hypersensitivity reactions to medications. Immunol Allergy Clin North Am. 2009;29(3):585–606. 10.1016/j.iac.2009.04.012 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation
57. Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; et al. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol. 2010;105(4):259–73. 10.1016/j.anai.2010.08.002 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation
58. Moffitt JE, Golden DB, Reisman RE, et al.: Stinging insect hypersensitivity: a practice parameter update. J Allergy Clin Immunol. 2004;114(4):869–86. 10.1016/j.jaci.2004.07.046 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation
59. Committee on Insects: The discontinuation of Hymenoptera venom immunotherapy. J Allergy Clin Immunol. 1998;101(5):573–5. 10.1016/S0091-6749(98)70161-7 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation
60. Golden DB, Kwiterovich KA, Kagey-Sobotka A, et al.: Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol. 1996;97(2):579–87. 10.1016/S0091-6749(96)70302-0 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation
61. Lerch E, Müller UR: Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J Allergy Clin Immunol. 1998;101(5):606–12. 10.1016/S0091-6749(98)70167-8 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation
62. Metcalfe DD, Schwartz LB: Assessing anaphylactic risk? Consider mast cell clonality. J Allergy Clin Immunol. 2009;123(3):687–8. 10.1016/j.jaci.2009.02.003 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
63. Zanotti R, Lombardo C, Passalacqua G, et al.: Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels. J Allergy Clin Immunol. 2015;136(1):135–9. 10.1016/j.jaci.2014.11.035 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation
64. Maulitz RM, Pratt DS, Schocket AL: Exercise-induced anaphylactic reaction to shellfish. J Allergy Clin Immunol. 1979;63(6):433–4. 10.1016/0091-6749(79)90218-5 [PubMed] [CrossRef] [Google Scholar]
65. Sheffer AL, Austen KF: Exercise-induced anaphylaxis. J Allergy Clin Immunol. 1980;66(2):106–11. 10.1016/0091-6749(80)90056-1 [PubMed] [CrossRef] [Google Scholar]
66. Shadick NA, Liang MH, Partridge AJ, et al.: The natural history of exercise-induced anaphylaxis: survey results from a 10-year follow-up study. J Allergy Clin Immunol. 1999;104(1):123–7. 10.1016/S0091-6749(99)70123-5 [PubMed] [CrossRef] [Google Scholar]
67. Untersmayr E, Bakos N, Schöll I, et al.: Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients. FASEB J. 2005;19(6):656–8. 10.1096/fj.04-3170fje [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation
68. Steinke JW, Platts-Mills TA, Commins SP: The alpha-gal story: lessons learned from connecting the dots. J Allergy Clin Immunol. 2015;135(3):589–96; quiz 597. 10.1016/j.jaci.2014.12.1947 [PMC free article] [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation
69. Commins SP, Satinover SM, Hosen J, et al.: Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-alpha-1,3-galactose. J Allergy Clin Immunol. 2009;123(2):426–33. 10.1016/j.jaci.2008.10.052 [PMC free article] [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation
70. Bonadonna P, Perbellini O, Passalacqua G, et al.: Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol. 2009;123(3):680–6. 10.1016/j.jaci.2008.11.018 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation
71. Akin C, Scott LM, Kocabas CN, et al.: Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. Blood. 2007;110(7):2331–3. 10.1182/blood-2006-06-028100 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
72. Ravi A, Butterfield J, Weiler CR: Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α. J Allergy Clin Immunol Pract. 2014;2(6):775–8. 10.1016/j.jaip.2014.06.011 [PubMed] [CrossRef] [Google Scholar]
73. Wilkin JK, Wilkin O, Kapp R, et al.: Aspirin blocks nicotinic acid-induced flushing. Clin Pharmacol Ther. 1982;31(4):478–82. 10.1038/clpt.1982.63 [PubMed] [CrossRef] [Google Scholar]
74. Ditto AM, Harris KE, Krasnick J, et al.: Idiopathic anaphylaxis: a series of 335 cases. Ann Allergy Asthma Immunol. 1996;77(4):285–91. 10.1016/S1081-1206(10)63322-4 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation
75. Wong S, Yarnold PR, Yango C, et al.: Outcome of prophylactic therapy for idiopathic anaphylaxis. Ann Intern Med. 1991;114(2):133–6. 10.7326/0003-4819-114-2-133 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation
76. Jones JD, Marney SR, Jr, Fahrenholz JM: Idiopathic anaphylaxis successfully treated with omalizumab. Ann Allergy Asthma Immunol. 2008;101(5):550–1. 10.1016/S1081-1206(10)60296-7 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation
77. Warrier P, Casale TB: Omalizumab in idiopathic anaphylaxis. Ann Allergy Asthma Immunol. 2009;102(3):257–8. 10.1016/S1081-1206(10)60091-9 [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation
78. Demirtürk M, Gelincik A, Colakoğlu B, et al.: Promising option in the prevention of idiopathic anaphylaxis: omalizumab. J Dermatol. 2012;39(6):552–4. 10.1111/j.1346-8138.2012.01520.x [PubMed] [CrossRef] [Google Scholar] F1000 Recommendation